**ABSTRACT**

**BACKGROUND**

Late-onset preeclampsia (PE) is preeclampsia occurring after 34 weeks of gestational age or later. Cullin 1 (CUL1), a proangiogenic protein, is expressed in the placenta, where an imbalance between proangiogenic and antiangiogenic proteins during gestation can cause disturbance of trophoblast invasion. This defect results in vascular ischemia that may produce preeclampsia. The objective of this study was to determine the correlation between CUL1 as proangiogenic factor and late-onset preeclampsia.

**METHODS**

This study was of analytical observational cross-sectional design and involved 44 preeclampsia patients with ≥34 weeks of gestational age (late-onset PE). The CUL1 level in the subjects’ sera, taken before they gave birth, and in homogenates of their placenta, obtained per vaginam or by cesarean section, were examined by the ELISA technique. Statistical analysis was performed with the Spearman correlation test with significant p value of <0.05.

**RESULTS**

Median maternal age was 31 years and median gestational age was 37 weeks. Median serum CUL1 was 41.78 pg/mL and median placental homogenate CUL1 was 32.24 pg per milligram of total placental tissue protein. There was no significant correlation between serum CUL1 level and late-onset preeclampsia (r=-0.281; p=0.065). There was also no significant correlation between placental CUL1 level and late-onset preeclampsia (r=-0.166; p=0.281).

**CONCLUSION**

Serum CUL1 and placental CUL1 were not correlated with late-onset preeclampsia. However, this study indicated that low serum CUL1 tends to prolong gestational age in preeclampsia.

**Keywords:** CUL1, proangiogenic, serum, placenta, late-onset, preeclampsia
INTRODUCTION

Preeclampsia (PE) is the occurrence of hypertension with proteinuria at a gestational age of more than 20 weeks or immediately after delivery.\(^{(1)}\) Preeclampsia is the main cause of morbidity and mortality, both in mother and fetus. The global incidence of PE is around 2-8% of all pregnancies, with a maternal mortality rate of around 10%-15%.\(^{(2)}\)

The most recent PE classification is based on the categories early-onset and late-onset. Early-onset PE (<34 weeks) is generally associated with abnormal uterine arterial Doppler findings, fetal growth restriction (FGR), and adverse outcomes to both mother and newborn.\(^{(3,4)}\) On the other hand, late-onset PE (≥34 weeks) is mostly associated with a normal or slightly increased uterine resistance index, a low rate of fetal involvement, and has a more favorable perinatal outcome.\(^{(5)}\)

There are several hypotheses on PE etiology, such as genetic factors, immunological disorders, paternal factors, endothelial dysfunction, and placental ischemia due to trophoblast invasion of the spiral arteries. Placental ischemia causes various problems in pregnant women, such as hypertension and proteinuria and abnormal fetal growth. The ischemia is due to functional imbalance between proangiogenic and antiangiogenic factors, resulting in trophoblast invasion, and ultimately causing reduced perfusion of the fetoplacental unit.\(^{(6)}\) The distribution of angiogenic factors depends on gestational age.\(^{(7)}\) At the onset of a normal pregnancy, the proangiogenic factors are predominant, whereas at the end of pregnancy, the antiangiogenic factors take over, being required for delivery. The imbalance of angiogenic factors in PE results in a shallow cytotrophoblast endovascular invasion and inadequate vascular formation of the uterine vessels as compared with a normal pregnancy.\(^{(6)}\) As a result of the disturbed trophoblast invasion, there is no dilation of the spiral arteries, so causing increased vascular resistance, leading to the signs of hypertension and proteinuria in PE.\(^{(8)}\)

Examples of proangiogenic factors that play a role in trophoblast invasion are vascular endothelial growth factor (VEGF),\(^{(9)}\) placental growth factor (PIGF),\(^{(8)}\) transforming growth factor-beta1 (TGF-β1),\(^{(9)}\) insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3),\(^{(10)}\) matrix metalloproteinase (MMP),\(^{(11)}\) Cullin 1 (CUL1),\(^{(12)}\) Cullin 3 (CUL3),\(^{(13)}\) Cullin 4A (CUL4A),\(^{(14,15)}\) and Cullin 7 (CUL7).\(^{(16)}\)

With regard to the association between angiogenic factors and late-onset PE, Soto et al.\(^{(17)}\) found an imbalance between proangiogenic and antiangiogenic factors in patients with late-onset PE, with or without placental lesions and consistent with maternal under perfusion. In contrast, Schaarschmidt et al.\(^{(18)}\) found increased antiangiogenic factors in early-onset PE, with sFlt-1 being higher than in late-onset PE, and a sharp decline in proangiogenic PIGF levels as compared with late-onset PE, and yielding a higher soluble fms-like tyrosine kinase-1 (sFlt-1)/PIGF ratio as compared with late-onset PE. Meanwhile, Escudero et al.\(^{(19)}\) found increases in placental angiogenic factors in both early and late-onset PE.

CUL1 is a proangiogenic protein in humans from the cullin gene family and is an essential component of the SKP1-CUL1-F-box protein (SCF) E3 ubiquitin ligase complex. CUL1 consists of 776 amino acids and has a molecular weight of 89679 Daltons. The protein is found in the cytosol and nucleus, and in small amounts in the cytoskeleton, and is localized in chromosome 7q36.1.\(^{(20,21)}\) CUL1 belongs to the group of cullin-based ubiquitin ligases, that are a subtype of the RING-type ubiquitin ligases and form multi-subunit complexes.\(^{(22)}\)

CUL1 plays an important role in protein degradation and ubiquitination, and mediates protein ubiquitination for involvement in cell cycle progression, signal transduction, and transcription. In the SCF complex, CUL1 serves as a rigid scaffold for assembling of the SKP1 and RBX1 subunits.\(^{(23)}\) Knockout of CUL1 in mice produces
early embryonic lethality. Therefore CUL1 plays an essential role in embryonic development and contributes significantly to normal and malignant cellular processes. There is only a single study on CUL1 in connection with PE, namely the study of Zhang et al. showing that CUL1 stimulates human trophoblast invasion and dysregulation of CUL1 expression in patients with PE.

To date there is no information about studies on the association between CUL1 concentration and pregnancies with late-onset PE. The aim of this study was to determine the association between CUL1 concentration and gestational age in late-onset PE.

METHODS

Design of the study

This study was of analytical observational cross-sectional design and was conducted in Cipto Mangunkusumo Hospital (RSCM) and Budi Kemuliaan Hospital, Jakarta, Indonesia from April 2017 – January 2018.

Subjects of the study

The study sample comprised women with late-onset PE and gestational age of ≥34 weeks, who were more than 15 years old, and agreed to participate in this study by signing a declaration of informed consent. The exclusion criteria of the study subjects were diabetes mellitus and chronic renal failure. Venous blood samples and placentas were collected to a total of 44 samples from women with PE at gestational ages of ≥34 weeks who were delivered per vaginam or by cesarean section.

PE is defined and classified based on the criteria recommended by the American College of Obstetrics and Gynecologists (ACOG) in 2013, namely hypertension appearing and developing after 20 weeks of pregnancy (systolic pressure ≥140 mmHg and/or diastolic pressure ≥90 mmHg), and proteinuria (≥300 mg in 24-hr urine) or with protein-positive 1 (+) reading from midstream urine. Preeclampsia may be without proteinuria but must have one of the following symptoms: thrombocytopenia (<100,000/microliter), renal insufficiency (serum creatinine >1.1 mg/dL), abnormal liver function (two-fold increases in transaminases as compared to normal), pulmonary edema, and cerebral or visual disturbances.

Serum CUL1 measurement

A volume of 5 mL of maternal blood was collected less than 24 hours before delivery and subsequently processed into serum by centrifugation at 3500 RPM for 10 minutes. The serum was collected and stored at a temperature of -80°C. After the required number of blood samples was reached, the CUL1 level was determined (MyBiosource MBS921353) by means of the ELISA technique according to the protocol from MyBiosource.

Placental CUL1 measurement

The placental cotyledons (maternal side) were cut up into cubes of 0.5x0.5x0.5 cm immediately after vaginal delivery or delivery by cesarean section. A total of 100 mg of placental tissue was washed in PBS and then processed to obtain a homogenate in 1 mL of PBS and stored at -80°C. After the required number of placental samples was reached, the CUL1 level was determined (MyBiosource MBS921353) by means of the ELISA technique according to the protocol from MyBiosource.

Ethical clearance

This study obtained ethical clearance from the Health Research Ethics Committee, Faculty of Medicine, Universitas Indonesia, under No. 34/UN2.F1/ETIK/2017.

Statistical analysis

The normality of the data was determined using the Kolmogorov-Smirnov test. Since the data turned out to be non-normally distributed, the non-parametric Spearman correlation test was used to determine the association of serum CUL1 and placental CUL1 levels with late-onset PE. A p-value of <0.05 was considered significant.
RESULTS

Table 1 shows that the median age was 31 years and the median gestational age 37 weeks. Median systolic blood pressure was 160 mmHg and median diastolic blood pressure 100 mmHg. Median qualitative urinary protein reading was 2.

Median serum CUL1 was 41.78 pg/mL and median placental homogenate CUL1 was 32.24 pg/mg of placental tissue protein. Median total placental tissue protein was 9.82 mg/mL. Placental CUL1 level was calculated from homogenate CUL1 divided by total placental tissue protein, to obtain pure CUL1 protein per total placental tissue protein.

In Table 2 it is apparent that there was no significant association between PE maternal serum CUL1 concentration and gestational age of ≥34 weeks (r=-0.281; p=0.065). Similarly, there was no significant association between placental CUL1 concentration and gestational age of ≥34 weeks (r=-0.166; p=0.281).

DISCUSSION

Late-onset PE is PE occurring at 34 weeks of pregnancy or later. There are few studies on late-onset PE in connection with angiogenic factors, including studies on CUL1 as proangiogenic factor in pregnancy. There are indeed several studies on CUL1, but not in connection with PE in pregnancy. The study conducted by Choudhury et al.(25) showed that CUL1 is part of the SCF complex that mediates ubiquitin-dependent cyclin G1 degradation and cyclin-dependent kinase inhibitors. The SCF complex consists of Skp, Cullin, and the F-box containing complex. Staropoli et al.(26) proved that the F-box and WD40 domain protein 7 (FBXW7) and CUL1 are located inside a distinct ubiquitin ligase complex that targets its ligase activity on cyclin E in the regulation of neuronal apoptosis. Deficiency of the SCF-Skp2 E3 ligase complex results in breast cancer metastases, impaired RhoA expression, cell migration, and cell invasion.(27)

Our study comprises 44 samples from PE study subjects with gestational age of ≥34 weeks. According to the categories of early- and late-onset PE, a gestational age of ≥34 weeks belongs to the late-onset category.(4) Theoretically, in a normal pregnancy, the later the gestational age, the lower the concentrations of proangiogenic proteins, followed by increased concentrations of antiangiogenic proteins. In PE the conditions are reversed, where the antiangiogenic concentrations are increased at the onset of pregnancy.(6) However, there are as yet no further insights in connection with the changes in proangiogenic protein concentrations in patients with PE. Fu et al. found another member of the cullin family, i.e. CUL7, that in the form of the CUL7 E3 ligase increases trophoblast migration and induces trophoblast epithelial-mesenchymal transition (EMT) through upregulated expression of ZEB1 and SLUG, two repressors of E-cadherin transcription.(16) Zhang et al.(13) in their study

Table 1. Distribution of features characteristics of the subjects

<table>
<thead>
<tr>
<th>Variable</th>
<th>n</th>
<th>Median</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal age (years)</td>
<td>44</td>
<td>31</td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>44</td>
<td>37</td>
</tr>
<tr>
<td>Systolic pressure (mmHg)</td>
<td>43</td>
<td>160</td>
</tr>
<tr>
<td>Diastolic pressure (mmHg)</td>
<td>43</td>
<td>100</td>
</tr>
<tr>
<td>Urinary protein (qualitative)</td>
<td>32</td>
<td>2</td>
</tr>
<tr>
<td>Serum CUL1 (pg/mL)</td>
<td>44</td>
<td>41.78</td>
</tr>
<tr>
<td>Placental CUL1 (pg/mg)</td>
<td>44</td>
<td>32.24</td>
</tr>
<tr>
<td>Placental protein (mg/mL)</td>
<td>44</td>
<td>9.83</td>
</tr>
</tbody>
</table>

Table 2. Association between CUL1 concentration and gestational age of ≥34 weeks

<table>
<thead>
<tr>
<th>Variables</th>
<th>r</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum CUL1 – gestational age of ≥34 weeks</td>
<td>-0.281</td>
<td>0.065</td>
</tr>
<tr>
<td>Homogenate CUL1 – gestational age of ≥34 weeks</td>
<td>-0.166</td>
<td>0.281</td>
</tr>
</tbody>
</table>

r = Spearman correlation coefficient
on CUL3 found that CUL3 plays a role in increased trophoblast invasion and migration and the occurrence of CUL3 dysregulation may cause PE. However, there is just a single study on CUL1 in connection with trophoblast invasion in PE. Zhang et al. (12) found by means of real-time q PCR and western blot assays, that CUL1 expression significantly decreases in primary human placental cytotrophoblast during syncytialization. CUL1 expression was significantly lower in placental villi in preeclampsia, as compared with equivalent placental controls. These investigators also found that CUL1 plays a role in enabling trophoblast invasion.

The study subjects used by Zhang et al. were PE patients aged 23-35 years with mature pregnancies (36-40 weeks). In contrast, our study used study subjects of age 20-43 years and did not find any association between PE gestational age of ≥34 weeks and CUL1 concentration, both in serum and placental homogenate. Since Zhang et al. (12) did not determine the serum CUL1 concentration in patients with PE, there can be no comparison of serum CUL1 concentration in patients with PE with those of controls. The theory expressed by Tomimatsu et al. (6) does not mention decreased proangiogenic protein concentration as one of the causes of PE, but that imbalances in angiogenic factors are one of the causes of PE, either through early or excessive antiangiogenic protein production. Further studies are needed to determine the extent of proangiogenic factor involvement in PE angiogenic factor imbalance.

Our study did not include the gestational age of <34 weeks, so that it is not possible to compare the changes in CUL1 concentration between late-onset (≥34 weeks) and early-onset pregnancy. In our study no normal pregnancies were used, which is one of the limitations of this study. The knowledge about the association of CUL1 concentration with gestational age is required to allow the use of the CUL1 concentration as a marker for monitoring PE development in connection with gestational age.

CONCLUSIONS

The serum CUL1 concentration as well as the placental CUL1 concentration are not associated with PE gestational age of ≥34 weeks. Further studies are needed using PE gestational age of ≤34 weeks to determine the presence or absence of differences in CUL1 concentrations between these differing pregnancy groups. These studies are needed to determine the extent of the role of angiogenic factors, in this case CUL1, in connection with PE development by gestational age.

CONFLICT OF INTEREST

Competing interest: no relevant disclosures.

ACKNOWLEDGMENT

This study was funded by the Directorate of Research and Community Service, Directorate General of Research and Development Reinforcement, Indonesian Ministry of Research, Technology, and Higher Education (No: 011/KM/BAP/I/PNT/2018).

CONTRIBUTORS

TDS contributed to compilation of the subject matter, writing of the manuscript drafts, data collection, and data analysis. IKL contributed to manuscript finalization. ARP contributed to the study concept and design. A contributed to manuscript revision. All authors have read and approved the final manuscript.

REFERENCES


